Abstract
CAR-T Cell therapy is an exciting and innovative therapy that has just recently been FDA approved for pediatric brain tumor patients at Seattle Children’s Hospital. It is a phase one study of CD-4 and CD-8 T cells, infused through indwelling catheters into the resection cavity or ventricular system of patients with recurrent or refractory brain tumors. In order to best support these patients, much of the supportive care data will need to be extrapolated through the experiences of CAR-T cell therapy in leukemia and other solid tumors. Cytokine-release Syndrome is of particular concern in all patients receiving CAR-T cells, and many clinical care strategies have been learned through prior clinical trials. The focus of this presentation will be to provide algorithms that structure care for cytokine-release syndrome post CAR-T cell infusion, and unique issues that are faced by pediatric brain tumor patients. Case studies will be provided and discussed to illustrate the clinical course of this complex therapy.